Диссертация (1139917), страница 18
Текст из файла (страница 18)
/ I. Bondarenko, A. Luft, P.Serwatowski, F. Barlesi, R. Chacko R. et al. // Ann. Oncol. –2013 –№24(1) – P. 75–83.182.Reichert J.M. Marketed therapeutic antibodies compendium. // MAbs.–2012. – № 4 – P. 413–415183.Robert C. Ipilimumab plus dacarbazine for previously untreatedmetastatic melanoma. / L.
Thomas, I. Bondarenko, S. O’Day, J. Weber, C. Garbe.etal. // N. Engl. J. Med –2011–№ 364(26) – P. 2517–26.184.Robinson J.A. Max Bergmann lecture Protein epitope mimetics in theage of structural vaccinology // J. Pept. Sci. – 2013 – № 19 – P. 127–140.185.Rosenberg S.A. Durable complete responses in heavily pretreatedpatients with metastatic melanoma using T-cell transfer immunotherapy / J.C.
Yang,R.M. Sherry, U.S. Kammula, M.S. Hughes, G.Q. Phan et al. // Clin. Cancer Res. –2011 –№ 17(13) –P. 4550–7.186.Rueckert C. Vaccines: from empirical development to rational design /C. Rueckert, C.A. Guzma´n. // PLoS Pathog. – 2012. – № 8 (11) – Art e1003001.187.Sangiolo D. Cytokine induced killer cells as promising immunotherapyfor solid tumors. // J Cancer. –2011. – № 2– P. 363–8.141188.Saiki, I. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages / I.Saiki, IJ.
Fidler // J Immunol. – 1985. – № 135(1). – Р. 684–8.189.Scorciapino M.A. Antimicrobial peptidomimetics: reinterpreting natureto deliver innovative therapeutics / M.A. Scorciapino, A.C. Rinaldi. // FrontImmunol. –2012. –№ 3 – Art 171.190.Shafique M. Induction of mucosal and systemic immunity againstrespiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2ligands / M. Shafique, J. Wilschut, A. de Haan. // Vaccine – 2012.
– №30: – P. 597–606.191.Shafique M. Evaluation of an intranasal virosomal vaccine againstrespiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on inductionof systemic and mucosal immune responses. / M. Shafique, T. Meijerhof, J.Wilschut, A. de Haan. // PLoS One – 2013. – №8 (4) – Art e61287.192.Shiba TOS. Synthesis of 6-O-mycoloyl- N-acetylmuramyl-L-alanyl-D-isoglutamine with antitumor activity /TOS. Shiba, S. Kusumoto // Bull Chem SocJpn – 1978.
– № 51 – P. 3307–11.193.ShinkaiK.Cryopyrin-associatedperiodicsyndromesandautoinflammation / K. Shinkai, T.H. McCalmont, K.S. Leslie. // Clin. Exp.Dermatol. – 2008. – №33 –P.19.194.Simcic SWB. Modulation of tumor necrosis factor production withdesmuramyldipeptide analogs / SWB. Simcic, M. Sollner, U. Urleb, S.
Gobec //Pflug Arch Eur J Phy. – 2000. – № 440 – P. 64–66.195.Smith P.M. The gut microbiota and mucosal T cells/ P.M. Smith W.S.Garrett. // Front Microbiol –2011. – № 2 – Art. 111. doi: 10.3389/fmicb.2011.00111196.Stegmann T. Lipopeptide-adjuvanted respiratory syncytial virusvirosomes: A safe and immunogenic non-replicating vaccine formulation. / T.Stegmann, T. Kamphuis, T.
Meijerhof et al. // Vaccine. – 2010. – № 28 – P. 5543–5550.142197.Sun JC. NK cells and immune “memory.” / J.C. Sun, S. Lopez-Verges,CC. Kim, JL. DeRisi, LL. Lanier LL // Journal of immunology (Baltimore, Md :1950). – 2011 – № 186(4) – P. 1891-1897.198.Steinhagen F. TLR-based immune adjuvants / F. Steinhagen, T. Kinjo,C. Bode, D.M.Klinman. // Vaccine –2010.
– № 29 – P. 3341–3355199.GobecSUU.SynthesisofPhosphonophthalimido-desmuramyldipeptide analogs Phosphorous, Sulfur and Silicon / SUU. Gobec //Relat Elem. – 2000. – №156 – P. 125–33.200.Siriwardena AJMR. Synthesis and proinflammatory effect ofpeptidoglycan-derived neoglycopeptide polymers / AJMR.Siriwardena, MA.Wolfert, ML. Vandenplas, JN. Moore, G-J. Boons // J. Am. Chem. Soc. – 2001. –№ 123 – P. 8145–46.201.Souvannavong, V. Muramyl dipeptide (MDP) synergizes withinterleukin 2 and interleukin 4 to stimulate, respectively, the differentiation andproliferation of B cells / V.
Souvannavong, S. Brown, A. Adam // Cell Immunol. –1990. – № 126(1). – Р. 106–16.202.Srividya, S. Selective activation of antitumor activity of macrophagesby the delivery of muramyl dipeptide using a novel polynucleotide-based carrierrecognized by scavenger receptors / S.
Srividya, RP. Roy, SK. Basu, A.Mukhopadhyay // Biochem. Biophys. Res. Commun. – 2000. – № 268(3). – Р. 772–7.203.Szilagyi LPP. Structual aspects of peptides with immunomodulatingactivity / LPP. Szilagyi // Mini Rev. Med. Chem. –2007.
– № 7 – P. 861–70.204.Takada, H. Structural characteristics of peptidoglycan fragmentsrequired to primemice for inductionof anaphylactoidreactionsbylipopolysaccharides / H. Takada, Y. Kawabata, S. Kawata, S. Kusumoto// InfectImmun. – 1996. – № 64(2). – Р. 657–9.205.Takada, H. Enhancement of endotoxin activity by muramyldipeptide /H.
Takada, S. Yokoyama, S. Yang // J Endotoxin Res. – 2002. – № 8(5). – Р. 337–342.143206.Taverniti V. The immunomodulatory properties of probioticmicroorganisms beyond their viability (ghost probiotics: proposal of paraprobioticconcept) / V. Taverniti, S. Guglielmetti // Genes. Nutr.– 2011– № 6 (3): – P.261–274207.Treating infectious diseases in a microbial world: Report of twoworkshops on novel antimicrobial therapeutics // Washington National AcademiesPress –2006.208.Torre L.A.
Global cancer statistics. / L.A. Torre, F. Bray, R.L. Siegel,Ferlay J. Lortet-Tieulent, A. Jemal // 2012. CA Cancer J Clin. – 2015.–№65(2) – P.87–108209.Tsuchida, K.Detection of peptidoglycan and endotoxin in dialysate,using silkworm larvae plasma and limulus amebocyte lysate methods / K. Tsuchida,Y. Takemoto, S. Yamagami, H.Edney, M. Niwa, M. Tsuchiya, T.
Kishimoto, S.Shaldon // Nephron. – 1997. – № 75(4). – Р. 438–43.210.Traub, S.MDP and other muropeptides-direct and synergistic effects onthe immune system / S. Traub, S. von Aulock, T. Hartung, C. Hermann // JEndotoxin Res. – 2006. – № 12(2). – Р. 69–85.211.Traub, S. Structural requirements of synthetic muropeptides tosynergize with lipopolysaccharide in cytokine induction / S. Traub, N.
Kubasch, S.Morath, M. Kresse, T. Hartung, RR. Schmidt, C. Hermann// J Biol Chem. – 2004. –№ 279(10). –Р. 8694–700.212.Urleb UGS. Synthesis and activity of phosphono desmuramyldipeptideanalogs / UGS. Urleb, D. Prelog. // Lett Pept Sci. – 1995. – № 2 – P. 193–97.213.Urleb UGS. Synthesis of new adamantine substituted acyclic MDPanalogs related to LK415 / UGS. Urleb //Acta Pharm. – 2000. – № 50 – P. 173–84.214.Vermeulen, MW. Differential mRNA responses in human macrophagesactivated by interferon-gamma and muramyl dipeptide / MW. Vermeulen // J.Immunol.
– 1987. – № 139(1). – Р. 7–9.215.Vogel, FR. Improving vaccine perform D1 in host recognition ofbacterial peptidoglycan containing diaminopimelic acid / FR. Vogel, M.144Chamaillard, M. Hashimoto, Y. Horie, J. Masumoto, S. Qiu, L. Saab, Y. Ogura, A.Kawasaki, K. Fukase, S. Kusumoto, MA. Valvano, SJ. Foster, TW. Mak, G. Nunez,N. Inohara, et al. // Nat Immunol. – 2003. – № 4(7). / Clin Infect Dis. – 2000.
– №30(Suppl 3) – Р. 266–70.216.Vollmer, W. Peptidoglycan structure and architecture / W. Vollmer, D.Blanot, MA. de Pedro // FEMS Microbiol Rev. – 2008. – № 32(2). – Р. 149–67.217.Wang Z-FXJ-C. Synthesis of fluoro-containing muramyl dipeptideanalogs / Z-FXJ-C. Wang //Tetrahedron. – 1998. – № 54 – P. 12597–608.218.Watanabe, T.
NOD2 negative regulator of Toll-like receptor 2 is a-mediated T helper type 1 responses / T. Watanabe, A. Kitani, PJ. Murray, W. Strober// Nat. Immunol. – 2004. –№ 5(8) – P. 800–8.219.Watanabe, T. Nucleotide binding oligomerization domain 2 deficiencyleads to dysregulated TLR2 signaling and induction of antigen-specific colitis /T.Watanabe, A.
Kitani, PJ. Murray, Y. Wakatsuki, IJ. Fuss, W. Strober // Immunity. –2006. – № 25(3) – P. 473–85.220.Wang, JE. Peptidoglycan primes for LPS-induced release ofproinflammatory cytokines in whole human blood / JE. Wang, PF. Jorgensen,EA.Ellingsen, M.Almiof, C. Thiemermann, SJ. Foster, AO. Aasen, R. Solberg //Shock. – 2001. – № 16(3). – Р. 178–82.221.Warren, HS. Current status of immunological adjuvants // HS Warren,FR Vogel, LA Chedid //Annu Rev Immunol. – 1986. – № 4. – Р.
369–88.222.Weng D.S., Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellularcarcinomas / J. Zhou, Q.M. Zhou, M. Zhao, Q.J. Wang, L.X. Huang et al. //. J.Immunother. – 2008 – № 31(1) – P. 63–71.223.Wehkamp, J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
